Cargando…
Short-course radiotherapy for rectal cancer: real-world evidence in Argentina
BACKGROUND: Short-course radiotherapy (SCRT) of 25 Gy in five daily fractions is a recommended strategy in the neoadjuvant setting for resectable locally advanced rectal cancer (LARC), as well as in cases of metastatic disease for local control. There is scarce information regarding the use of SCRT...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310334/ https://www.ncbi.nlm.nih.gov/pubmed/37396101 http://dx.doi.org/10.3332/ecancer.2023.1555 |
_version_ | 1785066516856700928 |
---|---|
author | Tissera, Natalia S Freile, Berenice Waisberg, Federico Esteso, Federico Galli, Mariana Loria, Fernando Sanchez Luca, Romina Pedraza, Ivana Inés Enrico, Diego Hernán Chacón, Carolina Huertas, Eduardo Chacón, Matías Rodrigo O’Connor, Juan Manuel |
author_facet | Tissera, Natalia S Freile, Berenice Waisberg, Federico Esteso, Federico Galli, Mariana Loria, Fernando Sanchez Luca, Romina Pedraza, Ivana Inés Enrico, Diego Hernán Chacón, Carolina Huertas, Eduardo Chacón, Matías Rodrigo O’Connor, Juan Manuel |
author_sort | Tissera, Natalia S |
collection | PubMed |
description | BACKGROUND: Short-course radiotherapy (SCRT) of 25 Gy in five daily fractions is a recommended strategy in the neoadjuvant setting for resectable locally advanced rectal cancer (LARC), as well as in cases of metastatic disease for local control. There is scarce information regarding the use of SCRT for patients who have received nonoperative management. OBJECTIVES: To describe the characteristics of patients who received treatment with SCRT for LARC and metastatic rectal cancer, toxicity, and the approach after radiation treatment. METHODS: This is a retrospective analysis of all patients who underwent SCRT for rectal cancer at the Alexander Fleming Institute from March 2014 to June 2022. RESULTS: In total, 44 patients were treated with SCRT. The majority were male (29, 66%), with a median age of 59 years (interquartile range 46–73). Most patients had stage IV disease (26, 59.1%), followed by LARC (18, 40.9%). Most lesions were located in the middle rectum (30, 68%). The majority of LARC patients underwent SCRT followed by consolidation chemotherapy (ChT) (16/18, 89%), while most patients with metastatic disease underwent SCRT followed by consolidation ChT (14/26, 53.8%). A clinical complete response (cCR) was documented in 8/44, 18.2% of patients. Most patients with LARC and cCR were managed by a watch and wait approach (5/18, 27.7%). Local recurrence was observed in LARC cases (2/18, 11.1%). Patients who underwent SCRT following consolidation ChT were more likely to have adverse events (AEs) than those undergoing induction ChT following SCRT (11/30, 36.7% versus 3/12, 25%, p = 0.02) CONCLUSION: In a subgroup of patients diagnosed with LARC and treated with SCRT followed by ChT, surgical treatment could be omitted after they achieved a cCR. Local recurrence was similar to that reported in a previous study. SCRT is a reasonable option for local disease control in stage IV disease, yielding low toxicity rates. Therefore, decisions must be made by a multidisciplinary team. Prospective studies are necessary to reach further conclusions. |
format | Online Article Text |
id | pubmed-10310334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-103103342023-06-30 Short-course radiotherapy for rectal cancer: real-world evidence in Argentina Tissera, Natalia S Freile, Berenice Waisberg, Federico Esteso, Federico Galli, Mariana Loria, Fernando Sanchez Luca, Romina Pedraza, Ivana Inés Enrico, Diego Hernán Chacón, Carolina Huertas, Eduardo Chacón, Matías Rodrigo O’Connor, Juan Manuel Ecancermedicalscience Short Communication BACKGROUND: Short-course radiotherapy (SCRT) of 25 Gy in five daily fractions is a recommended strategy in the neoadjuvant setting for resectable locally advanced rectal cancer (LARC), as well as in cases of metastatic disease for local control. There is scarce information regarding the use of SCRT for patients who have received nonoperative management. OBJECTIVES: To describe the characteristics of patients who received treatment with SCRT for LARC and metastatic rectal cancer, toxicity, and the approach after radiation treatment. METHODS: This is a retrospective analysis of all patients who underwent SCRT for rectal cancer at the Alexander Fleming Institute from March 2014 to June 2022. RESULTS: In total, 44 patients were treated with SCRT. The majority were male (29, 66%), with a median age of 59 years (interquartile range 46–73). Most patients had stage IV disease (26, 59.1%), followed by LARC (18, 40.9%). Most lesions were located in the middle rectum (30, 68%). The majority of LARC patients underwent SCRT followed by consolidation chemotherapy (ChT) (16/18, 89%), while most patients with metastatic disease underwent SCRT followed by consolidation ChT (14/26, 53.8%). A clinical complete response (cCR) was documented in 8/44, 18.2% of patients. Most patients with LARC and cCR were managed by a watch and wait approach (5/18, 27.7%). Local recurrence was observed in LARC cases (2/18, 11.1%). Patients who underwent SCRT following consolidation ChT were more likely to have adverse events (AEs) than those undergoing induction ChT following SCRT (11/30, 36.7% versus 3/12, 25%, p = 0.02) CONCLUSION: In a subgroup of patients diagnosed with LARC and treated with SCRT followed by ChT, surgical treatment could be omitted after they achieved a cCR. Local recurrence was similar to that reported in a previous study. SCRT is a reasonable option for local disease control in stage IV disease, yielding low toxicity rates. Therefore, decisions must be made by a multidisciplinary team. Prospective studies are necessary to reach further conclusions. Cancer Intelligence 2023-06-01 /pmc/articles/PMC10310334/ /pubmed/37396101 http://dx.doi.org/10.3332/ecancer.2023.1555 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Tissera, Natalia S Freile, Berenice Waisberg, Federico Esteso, Federico Galli, Mariana Loria, Fernando Sanchez Luca, Romina Pedraza, Ivana Inés Enrico, Diego Hernán Chacón, Carolina Huertas, Eduardo Chacón, Matías Rodrigo O’Connor, Juan Manuel Short-course radiotherapy for rectal cancer: real-world evidence in Argentina |
title | Short-course radiotherapy for rectal cancer: real-world evidence in Argentina |
title_full | Short-course radiotherapy for rectal cancer: real-world evidence in Argentina |
title_fullStr | Short-course radiotherapy for rectal cancer: real-world evidence in Argentina |
title_full_unstemmed | Short-course radiotherapy for rectal cancer: real-world evidence in Argentina |
title_short | Short-course radiotherapy for rectal cancer: real-world evidence in Argentina |
title_sort | short-course radiotherapy for rectal cancer: real-world evidence in argentina |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310334/ https://www.ncbi.nlm.nih.gov/pubmed/37396101 http://dx.doi.org/10.3332/ecancer.2023.1555 |
work_keys_str_mv | AT tisseranatalias shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT freileberenice shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT waisbergfederico shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT estesofederico shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT gallimariana shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT loriafernandosanchez shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT lucaromina shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT pedrazaivanaines shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT enricodiegohernan shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT chaconcarolina shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT huertaseduardo shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT chaconmatiasrodrigo shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina AT oconnorjuanmanuel shortcourseradiotherapyforrectalcancerrealworldevidenceinargentina |